<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753207</url>
  </required_header>
  <id_info>
    <org_study_id>06-30 ICORG</org_study_id>
    <secondary_id>ICORG-06-30</secondary_id>
    <secondary_id>ICORG-109403</secondary_id>
    <secondary_id>EUDRACT-2007-002327-33</secondary_id>
    <secondary_id>EU-20875</secondary_id>
    <nct_id>NCT00753207</nct_id>
    <nct_alias>NCT00566748</nct_alias>
  </id_info>
  <brief_title>Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30</brief_title>
  <official_title>An Open-Label Phase I Study of Fixed Dose Lapatinib in Combination With an Escalating Dose of Epirubicin in Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Trials Ireland</source>
  <brief_summary>
    <textblock>
      RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving lapatinib together with epirubicin may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of epirubicin when&#xD;
      given together with lapatinib in treating patients with metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the safety and tolerability of fixed-dose lapatinib ditosylate in combination&#xD;
           with epirubicin hydrochloride in patients with metastatic breast cancer.&#xD;
&#xD;
        -  To determine the optimally-tolerated regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the clinical efficacy of this regimen in these patients.&#xD;
&#xD;
        -  To analyze pharmacokinetic data of this regimen.&#xD;
&#xD;
        -  To determine biomarkers that correlate with clinical benefit or response to lapatinib&#xD;
           ditosylate in these patients.&#xD;
&#xD;
      Tertiary&#xD;
&#xD;
        -  To identify tumor-derived or blood-derived biomarkers that correlate with or are&#xD;
           predictive of clinical response or benefit to lapatinib ditosylate in these patients.&#xD;
&#xD;
        -  To determine the levels of IGF-IR and phosphorylated IGF-IR in tumor tissue.&#xD;
&#xD;
        -  To determine the expression pattern of the proteins associated with drug resistance that&#xD;
           may be clinically active in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of epirubicin hydrochloride.&#xD;
&#xD;
      Patients receive oral lapatinib ditosylate followed by epirubicin hydrochloride IV over 15-30&#xD;
      minutes on day 1. Treatment repeats every 3 weeks for up to 7 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood samples are collected periodically for pharmacokinetic analysis via liquid&#xD;
      chromatography-mass spectometry (LC-MS).&#xD;
&#xD;
      After completion of study therapy, patients are followed at 28 days and then every 3 months&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimally-tolerated regimen of lapatinib ditosylate in combination with epirubicin hydrochloride</measure>
    <time_frame>2012</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of this regimen in terms of objective tumor response rate and disease progression as assessed by standard RECIST criteria</measure>
    <time_frame>2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between baseline expression of intra-tumoral biomarkers (e.g., ErbB1, ErbB2, insulin-like growth factor-1 receptor, p-AKT, and ERK) and clinical response or benefit to lapatinib ditosylate by IHC</measure>
    <time_frame>2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between expression pattern of drug resistance proteins (e.g., p-glycoprotein, MRP1, BCRP, and MDR-3) and clinical response or benefit to lapatinib ditosylate by IHC</measure>
    <time_frame>2012</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Lapatinib and Epirubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose of lapatinib in combination with escalating dose of epirubicin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
    <arm_group_label>Lapatinib and Epirubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib ditosylate</intervention_name>
    <arm_group_label>Lapatinib and Epirubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biomarker analysis</intervention_name>
    <arm_group_label>Lapatinib and Epirubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <arm_group_label>Lapatinib and Epirubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>liquid chromatography</intervention_name>
    <arm_group_label>Lapatinib and Epirubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mass spectrometry</intervention_name>
    <arm_group_label>Lapatinib and Epirubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Confirmed diagnosis of breast cancer&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  No de novo metastasis&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  ANC ≥ 1,500/μL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/μL&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  AST/ALT &lt; 3 times upper limit of the normal (ULN)&#xD;
&#xD;
          -  Total bilirubin normal (unless documented history of congenital hypobilirubinemia)&#xD;
&#xD;
          -  LVEF normal by ECHO or MUGA scan&#xD;
&#xD;
          -  Not pregnant or breastfeeding&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception from the time of their negative&#xD;
             pregnancy test before treatment, during treatment, and 28 days following treatment&#xD;
&#xD;
          -  Able to swallow and retain oral medication&#xD;
&#xD;
          -  History of other malignancies (e.g., cervical carcinoma in situ, melanoma in situ, or&#xD;
             basal cell or squamous cell carcinoma of the skin) allowed provided patient has been&#xD;
             treated and disease free ≥ 5 years and deemed by the investigator to be at low risk&#xD;
             for recurrence&#xD;
&#xD;
          -  No known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to lapatinib ditosylate or excipients&#xD;
&#xD;
          -  No malabsorption syndrome, disease significantly affecting gastrointestinal function,&#xD;
             resection of the stomach or small bowel, or ulcerative colitis&#xD;
&#xD;
          -  No active or uncontrolled infection&#xD;
&#xD;
          -  No known history of uncontrolled or symptomatic angina, arrhythmias, congestive heart&#xD;
             failure, or other cardiac disorders&#xD;
&#xD;
          -  No history of prolonged QT interval&#xD;
&#xD;
          -  No active hepatic or biliary disease (except for Gilbert's syndrome, asymptomatic&#xD;
             gallstones, liver metastases or stable chronic liver disease per investigator&#xD;
             assessment)&#xD;
&#xD;
          -  No concurrent disease or condition that would render the patient inappropriate for&#xD;
             study participation, or serious medical disorder that would interfere with the&#xD;
             patient's safety&#xD;
&#xD;
          -  No dementia, altered mental status, or psychiatric condition that would prohibit the&#xD;
             understanding or rendering of informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Prior radiotherapy for treatment of primary tumor allowed&#xD;
&#xD;
          -  Prior non-anthracycline based regimens in neoadjuvant, adjuvant, or metastatic setting&#xD;
             allowed&#xD;
&#xD;
          -  Prior adjuvant Herceptin® or ErbB inhibitors allowed provided disease progression was&#xD;
             &gt; 6 months after completion of treatment&#xD;
&#xD;
          -  More than 3 months since prior Herceptin®, ErbB1, or ErbB2&#xD;
&#xD;
          -  No prior chemotherapy in the adjuvant or neoadjuvant setting with anthracycline or&#xD;
             anthracenedione-containing regimens&#xD;
&#xD;
          -  More than 3 weeks since prior and no concurrent medications that would prolong QT&#xD;
             interval&#xD;
&#xD;
          -  More than 1 month or 5 half-lives (whichever is longer) since prior, no concurrent&#xD;
             investigational drugs&#xD;
&#xD;
          -  No unresolved or unstable, serious toxicity from prior investigational drug and/or&#xD;
             cancer treatment&#xD;
&#xD;
          -  At least 3 weeks since prior and no concurrent prohibited medications (i.e., CYP3A4&#xD;
             inducers or inhibitors)&#xD;
&#xD;
          -  No concurrent non-study anticancer therapy (i.e., chemotherapy, immunotherapy, or&#xD;
             biologic therapy)&#xD;
&#xD;
          -  No concurrent participation in another clinical trial&#xD;
&#xD;
          -  No concurrent grapefruit or grapefruit juice&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Crown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Vincent's University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Adelaide and Meath Hospital, Dublin Incorporating the National Childresn's Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>24</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James's Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>September 13, 2008</study_first_submitted>
  <study_first_submitted_qc>September 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <last_update_submitted>February 12, 2016</last_update_submitted>
  <last_update_submitted_qc>February 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

